Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-01-10, Stock:PFE, The news for the past five days is as follows:
2019-01-03: NEWS1: Why Johnson & Johnson Stock is Clearly Set to Rise Again.NEWS2: Why Johnson & Johnson Stock is Clearly Set to Rise Again.NEWS3: 3 Biopharma Stocks to Buy for Their Robust Dividend Yields.NEWS4: 3 Biopharma Stocks to Buy for Their Robust Dividend Yields.NEWS5: Why Johnson & Johnson Stock is Clearly Set to Rise Again.NEWS6: 3 Biopharma Stocks to Buy for Their Robust Dividend Yields.NEWS7: Will Pfizer's (PFE) Stock Keep Up the Momentum in 2019?.NEWS8: Will Pfizer's (PFE) Stock Keep Up the Momentum in 2019?.NEWS9: Will Pfizer's (PFE) Stock Keep Up the Momentum in 2019?.NEWS10: Pfizer Initiates Phase 2b/3 Clinical Trial for PF-06651600, an Oral JAK3 Inhibitor, for the Treatment of Patients with Moderate to Severe Alopecia Areata.
2019-01-04: NEWS1: Bristol To Become Top 5 Pharma — And Other Fallout From Celgene Takeover.NEWS2: Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate.NEWS3: Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate.NEWS4: Nektar, ImaginAb Enter Into Immuno-Oncology Collaboration.NEWS5: Nektar, ImaginAb Enter Into Immuno-Oncology Collaboration.NEWS6: Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate.NEWS7: Health Care Sector Update for 01/04/2019: FLKS, NVAX, ESPR, JNJ, PFE, ABT, MRK, AMGN.NEWS8: Health Care Sector Update for 01/04/2019: FLKS, NVAX, ESPR, JNJ, PFE, ABT, MRK, AMGN.NEWS9: Pfizer Begins Pivotal Study on Alopecia Areata Candidate.NEWS10: Pfizer Begins Pivotal Study on Alopecia Areata Candidate.NEWS11: Pfizer Rises 3%.NEWS12: Pfizer Begins Pivotal Study on Alopecia Areata Candidate.NEWS13: Today's Research Reports on Trending Tickers: Pfizer and Bristol-Myers Squibb.
2019-01-07: NEWS1: Aerie's Rhopressa Succeeds in Study on Japanese Patients.NEWS2: Aerie's Rhopressa Succeeds in Study on Japanese Patients.NEWS3: Top Dow Stocks for 2018.NEWS4: Pfizer (PFE) Gains But Lags Market: What You Should Know.NEWS5: Biogen Inks Two Deals to Make Drugs for Neurological Diseases.NEWS6: Biogen Inks Two Deals to Make Drugs for Neurological Diseases.NEWS7: Aerie's Rhopressa Succeeds in Study on Japanese Patients.NEWS8: Why Exact Sciences Soared Today.NEWS9: Biogen Inks Two Deals to Make Drugs for Neurological Diseases.NEWS10: Pfizer or Eli Lilly: Whose Revenue Is Growing More Quickly?.NEWS11: GlaxoSmithKline CEO Emma Walmsley gets &apos;radical&apos; about reshaping portfolio.NEWS12: GlaxoSmithKline CEO Emma Walmsley gets 'radical' about reshaping portfolio.NEWS13: Analysts’ Recommendations for Eli Lilly in January.NEWS14: Company News For Jan 7, 2019.NEWS15: Company News For Jan 7, 2019.NEWS16: IVV, GOOG, GOOGL, PFE: ETF Inflow Alert.NEWS17: IVV, GOOG, GOOGL, PFE: ETF Inflow Alert.NEWS18: GSK CEO: Pfizer venture creates value for both our consum....NEWS19: Analysts’ Recommendations for Pfizer in January.NEWS20: Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?.NEWS21: Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?.NEWS22: As Patent Expirations Loom, the Clock Is Ticking on AbbVie Stock.NEWS23: Company News For Jan 7, 2019.NEWS24: Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?.NEWS25: J.P. Morgan Healthcare Conference kicks off Monday with focus on Trump, Amazon.NEWS26: The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Merck, Pfizer and AbbVie.NEWS27: The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Merck, Pfizer and AbbVie.NEWS28: Pfizer To Present At The J.P. Morgan Conference; Webcast At 11:30 AM ET.NEWS29: Pfizer To Present At The J.P. Morgan Conference; Webcast At 11:30 AM ET.NEWS30: The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Merck, Pfizer and AbbVie.NEWS31: Pfizer To Use CytoReason's Machine Learning Model For Drug Discovery.NEWS32: Pfizer To Use CytoReason's Machine Learning Model For Drug Discovery.
2019-01-08: NEWS1: Pfizer or Eli Lilly: Which Company Is More Cost Efficient?.NEWS2: Dogs of the Dow Win in 2018: Will ETFs See Success in 2019?.NEWS3: Dogs of the Dow Win in 2018: Will ETFs See Success in 2019?.NEWS4: Health Care Sector Update for 01/08/2019: AXSM, AKRX, NVS, JNJ, PFE, MRK, ABT, AMGN.NEWS5: Health Care Sector Update for 01/08/2019: AXSM, AKRX, NVS, JNJ, PFE, MRK, ABT, AMGN.NEWS6: Pfizer or Eli Lilly: Which Company Has Better Margins?.NEWS7: 3 Companies You Don't Realize You Rely On Every Day.NEWS8: 3 Companies You Don't Realize You Rely On Every Day.NEWS9: Dogs of the Dow Win in 2018: Will ETFs See Success in 2019?.NEWS10: Pfizer or Eli Lilly: Whose Earnings Are Seeing Better Growth?.NEWS11: 3 Companies You Don&apos;t Realize You Rely On Every Day.NEWS12: 3 Things Pfizer's New CEO Just Said That Investors Will be Glad to Hear.NEWS13: 3 Things Pfizer's New CEO Just Said That Investors Will be Glad to Hear.NEWS14: 3 Things Pfizer&apos;s New CEO Just Said That Investors Will be Glad to Hear.NEWS15: Gilead, Pfizer Execs Suggest Even More Pharma M&A Is on Way.NEWS16: Pfizer (PFE) Gains But Lags Market: What You Should Know.NEWS17: Pfizer (PFE) Gains But Lags Market: What You Should Know.
2019-01-09: NEWS1: Pfizer to shut two manufacturing plants in India.NEWS2: 7 Dow Jones Stocks Set to Charge Higher.NEWS3: 7 Dow Jones Stocks Set to Charge Higher.NEWS4: JP Morgan's Dimon hosted a private dinner for pharma executives, and a major topic was Amazon.NEWS5: Pfizer to shut two manufacturing plants in India.NEWS6: Cell therapy pioneer eyes Bay Area manufacturing.NEWS7: Amarin Expects Expenses to Rise in the Future.NEWS8: See what the IHS Markit Score report has to say about Pfizer Inc..NEWS9: 3 Reasons Buying Celgene Right Now Makes Sense.NEWS10: 3 Reasons Buying Celgene Right Now Makes Sense.NEWS11: Pfizer or Eli Lilly: Which Company Has the Better Dividend Policy?.NEWS12: 3 Reasons Buying Celgene Right Now Makes Sense.

Answer: Decrease